Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Hereditary Sensory and Autonomic Neuropathies × chiauranib × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 2 Recurrence 1 Hereditary Sensory and Autonomic Neuropathies 1

Interventions

duvelisib 3 parsaclisib 1 obinutuzumab 1 liposomal doxorubicin 1 chiauranib 1 Taxes 1 Rituximab 1 Paclitaxel 1 Lomustine 1 Irinotecan 1 Gemcitabine 1 Doxorubicin 1 Carboplatin 1 Albumin-Bound Paclitaxel 1 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03074825 2019-07-24

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Chipscreen Biosciences, Ltd.

Phase 1 Terminated

Lymphoma, Non-Hodgkin, Hereditary Sensory and Autonomic Neuropathies, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡